Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 17/20 | 0.55 |
| ▸ | EGFR | P00533 | 17/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 13/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 13/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383068 | 0.87 | ERBB2 (0.63) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL5569967 | 0.83 | ERBB2 (0.58) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL3819424 | 0.82 | ERBB2 (0.70) | ERBB2EGFRERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL4033478 | 0.79 | EGFR (0.73) | ERBB2EGFR | |
| SCHEMBL24569546 | 0.78 | EGFR (0.51) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL29888194 | 0.78 | EGFR (0.51) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL4388238 | 0.78 | EGFR (0.48) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL4394647 | 0.78 | EGFR (0.48) | ERBB2EGFRERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL4032038 | 0.77 | EGFR (0.68) | ERBB2EGFR | |
| SCHEMBL4385188 | 0.77 | ERBB2 (0.68) | ERBB2EGFRERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | ERBB2 1/4885EGFR 3/4885ERBB3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.